TABLE 6.
Comparison of the pharmacokinetic/pharmacodynamic parameters between patients who developed linezolid resistance or decreased susceptibility in nasal, oropharyngeal, and intestinal microbiotas under treatment and patients who did not
| Type of microbiota (no. of patients colonized at D0) and variable | Resistance or decrease of susceptibility to linezolid during treatment, median value (range) |
P (Wilcoxon test) | |
|---|---|---|---|
| No | Yes | ||
| Nasal (26) | n = 24 | n = 2 | |
| AUC/MIC (h) | 98.0 (17.1–488.8) | 560.5 (167.2–953.7) | 0.12 |
| Cmax/MIC | 5.6 (1.1–35.2) | 28.5 (12.4–44.6) | 0.10 |
| AUC >MIC (mg/liter · h) | 223.7 (10.4–679.0) | 536.5 (143.2–929.7) | 0.55 |
| Time >MIC (h) | 24.0 (5.1–24.0) | 24.0 (14.8–24.0) | 0.88 |
| Oropharyngeal (17) | n = 14 | n = 3 | |
| AUC/MIC (h) | 142.3 (26.3–661.2) | 775.3 (137.2–953.7) | 0.12 |
| Cmax/MIC | 10.4 (3.1–35.6) | 41.5 (8.6–44.6) | 0.16 |
| AUC >MIC (mg/liter · h) | 168.6 (36.9–582.0) | 375.7 (56.6–929.7) | 0.43 |
| Time >MIC (h) | 24.0 (10.2–24.0) | 24.0 (24.0–24.0) | 0.73 |
| Intestinal (26) | n = 22 | n = 4 | |
| AUC/MIC (h) | 69.8 (17.1–476.9) | 131.3 (32.7–198.0) | 0.56 |
| Cmax/MIC | 4.4 (1.1–22.3) | 7.3 (2.6–10.4) | 0.71 |
| AUC >MIC (mg/liter · h) | 178.7 (10.4–905.7) | 259.5 (106.4–348.0) | 0.51 |
| Time >MIC (h) | 24.0 (5.1–24.0) | 24.0 (14.8–24.0) | 0.77 |